Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CPBIO Holding CoCAIHF 58 5-Year Yield-on-Cost % is 0.00 as of Aug. 31, 2026. GuruFocus rates CAIHF with a GF Score™ of 58/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 509 Drug Manufacturers companies, CPBIO Holding Co ranks worse than 196463.46% on this metric.
CPBIO Holding Co's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for CPBIO Holding Co's 5-Year Yield-on-Cost % or its related term are showing as below:
CAIHF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.39 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CPBIO Holding Co (OTCPK:CAIHF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
CPBIO Holding Co 5-Year Yield-on-Cost % Related Terms
CAIHF vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CPBIO Holding Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where CPBIO Holding Co's 5-Year Yield-on-Cost % falls into.
CPBIO Holding Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
CPBIO Holding Co (CAIHF) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CPBIO Holding Co and its competitors. According to the industry distribution chart, CPBIO Holding Co ranks #999999 out of 509 companies in the Drug Manufacturers industry.
Is CPBIO Holding Co's 5-Year Yield-on-Cost % too high?
CPBIO Holding Co's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, CPBIO Holding Co ranks #999999 out of 509 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CPBIO Holding Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CPBIO Holding Co ranks #999999 out of 509 companies for 5-Year Yield-on-Cost %. This places CPBIO Holding Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.39, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CPBIO Holding Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CPBIO Holding Co's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
Based on GuruFocus' analysis, CPBIO Holding Co (CAIHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.07 — trading 567.3% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. CPBIO Holding Co's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For CPBIO Holding Co (CAIHF), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CPBIO Holding Co (CAIHF) Overvalued in 2026?
Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued.
The current stock price of $1.07 is trading 567.3% above its estimated GF Value™ of $0.16.
GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.
Key valuation signals for CAIHF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $0.16 vs. price of $1.07 (567.3% above fair value)
No single metric tells the full story. See the CAIHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
58GF Score
Get the complete analysis for CAIHF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAIHF has been successfully added to your 
